clinical trial · NCT06748001
Avapritinib Rollover Study
Mastocytosis, SystemicAvapritinib
brief summary
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
started
Nov 28, 2024
primary completion
Dec 31, 2027
completion
Dec 31, 2027
last updated
Feb 9, 2026
official title
An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol